Study on the Efficacy and Safety of Transarterial Chemoembolization Combined with Targeted Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma

Launched by YAO XIE · Nov 28, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat patients with unresectable liver cancer, which means the cancer cannot be surgically removed. The study is testing a combination of two treatments: transarterial chemoembolization (TACE), a procedure that delivers chemotherapy directly to the tumor, and targeted immunotherapy, which helps the body’s immune system fight the cancer. The goal is to see how effective and safe this combination is for patients with this type of cancer.

To participate in the trial, patients need to be between 18 and 68 years old and have at least one measurable tumor. They should be in generally good health, with a good performance status meaning they can carry out normal activities. However, people with certain health issues, like uncontrolled high blood pressure or serious heart problems, cannot join. The study is not yet recruiting participants, but it aims to provide new treatment options for those dealing with this challenging condition. If eligible, participants can expect to receive close monitoring and care throughout the study.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria:Voluntarily join this study and sign the informed consent form;Age ≥18 years and ≤68 years, receiving arterial chemoembolization combined with targeted immunotherapy, regardless of gender;At least one measurable lesion as defined by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST);Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1;Child-Pugh score ≤7;Generally good condition, such as albumin \>25 g/L, white blood cells \>3×10\^9/L (excluding causes such as hypersplenism), platelets \>50×10\^9/L, etc.;Expected survival \>12 weeks;No fertility requirements.
• • Exclusion Criteria:Uncontrolled hypertension;Active autoimmune diseases;Concurrent other untreated malignancies;Pregnant or breastfeeding women;Active bleeding tendency or coagulation disorders;Severe liver, kidney, heart, or bone marrow dysfunction;Severe allergy to iodine contrast agents;Other contraindications to the use of TACE, lenvatinib, camrelizumab, atezolizumab, bevacizumab, etc.;The investigator believes that accompanying medical history may affect the subject's safe completion of the study.